Femoral artery stent Eluvia™

popliteal arterynitinolpolymer

Overview
Eluvia DES is a polymer-coated, paclitaxel-eluting nitinol vascular stent developed for treatment of disease in the superficial femoral artery (SFA) and proximal popliteal segments. It combines sustained, controlled drug release with a design aimed at flexibility and precise placement in challenging femoropopliteal anatomy.

How it works
Eluvia DES delivers paclitaxel to the target lesion over an extended period (beyond one year) via a durable polymer coating. The coating regulates release during the restenotic window, minimizes systemic washout, and concentrates the drug at the lesion site to reduce neointimal proliferation.

Key features

• Sustained, controlled paclitaxel release through a polymer coating matched to the SFA restenotic timeline.
• Design optimized for femoropopliteal disease: flexibility and precise stent deployment.
• Efficient target lesion drug delivery maintained for over one year.
• Low drug dose density among paclitaxel therapies: 0.167 µg/mm² (reported as ~18× lower than Zilver PTX).
• Consistent, durable clinical performance in complex SFA lesions.

Clinical evidence

• SPORTS RCT (Oct 2023): Investigator-sponsored, prospective, multicenter, three-arm RCT (Eluvia DES vs. BMS vs. DCB) in TASC C/D lesions. Eluvia arm included complex lesions (mean lesion length ~235 mm). Primary endpoint: percent diameter stenosis at 12 months — Eluvia showed statistically superior performance vs BMS; Eluvia demonstrated superior freedom from CD-TLR at 12 months.
• IMPERIAL RCT (Aug 2018): Head-to-head RCT comparing polymer-coated Eluvia DES to polymer-free paclitaxel-coated Zilver PTX for femoropopliteal lesions ≤140 mm. At 1 year, Eluvia achieved significantly higher primary patency vs Zilver PTX; at 2 years, fewer clinically driven TLRs versus Zilver PTX.
• EMINENT RCT (Oct 2022): Largest RCT (2:1) vs self-expanding bare-metal stents for SFA/proximal popliteal. Eluvia demonstrated superiority with 1-year primary patency (85.4% vs 76.3%) and greater sustained clinical improvement without reintervention through 1 year.

Ordering information (selection of commercial configurations)
Description | UPN | GTIN
Eluvia 6 mm x 40 mm x 130 cm | H74939294600410 | 08714729876571
Eluvia 6 mm x 60 mm x 130 cm | H74939294600610 | 08714729876588
Eluvia 6 mm x 80 mm x 130 cm | H74939294600810 | 08714729876595
Eluvia 6 mm x 100 mm x 130 cm | H74939294601010 | 08714729876601
Eluvia 6 mm x 120 mm x 130 cm | H74939294601210 | 08714729876618
Eluvia 6 mm x 150 mm x 130 cm | H74939294601510 | 08714729876625
Eluvia 7 mm x 40 mm x 130 cm | H74939294700410 | 08714729876694
Eluvia 7 mm x 60 mm x 130 cm | H74939294700610 | 08714729876700
Eluvia 7 mm x 80 mm x 130 cm | H74939294700810 | 08714729876717
Eluvia 7 mm x 100 mm x 130 cm | H74939294701010 | 08714729876724
Eluvia 7 mm x 120 mm x 130 cm | H74939294701210 | 08714729876731
Eluvia 7 mm x 150 mm x 130 cm | H74939294701510 | 08714729876748

Product literature (titles)

• Eluvia brochure
• Eluvia-Sports-Summary (SPORTS clinical trial summary)
• Eluvia IMPERIAL RCT 5yr Summary
• EMINENT 1yr summary
• Eluvia procedure coding and reimbursement guide
• Eluvia DES UPN and GTIN list

Caractéristiques / spécifications techniques

• Intended anatomy: superficial femoral artery (SFA) and proximal popliteal; polymer-coated paclitaxel-eluting nitinol stent.
• Polymer: designed for sustained, controlled paclitaxel release aligned with SFA restenotic process.
• Drug dose density: 0.167 µg/mm² (reported as lowest among PTX therapies).
• Drug delivery duration: efficient delivery designed to extend beyond one year.
• Available nominal stent diameters: 6 mm and 7 mm.
• Available stent lengths: 40 mm, 60 mm, 80 mm, 100 mm, 120 mm, 150 mm.
• Delivery system profile: 6F delivery for available diameter/length combinations.
• Ordering identifiers: UPNs and GTINs provided per configuration (see ordering information above).